Summary & Overview
HCPCS G9211: Hepatitis C Quantitative RNA Not Documented (4–12 Weeks)
HCPCS Level II code G9211 denotes a missing documentation of quantitative hepatitis C RNA testing between 4 and 12 weeks after starting antiviral therapy. This early on-treatment viral load check is an important clinical milestone used to assess response and guide management of hepatitis C treatment. Nationally, capture of these monitoring events affects quality measurement, reporting, and continuity of care for patients receiving direct-acting antivirals.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for the code, typical sites of service, and areas where documentation gaps are recorded. The analysis highlights benchmarks and policy-relevant considerations for payers and provider organizations, including quality measurement implications and administrative reporting tied to on-treatment HCV monitoring. The publication also outlines what the code signals about care processes and which operational domains (laboratory workflows, outpatient clinics, and billing reconciliation) are most relevant for follow-up. Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Billing Code Overview
HCPCS Level II code G9211 indicates that hepatitis C quantitative RNA testing was not documented as performed between 4–12 weeks after the initiation of antiviral treatment, reason not given. The code captures a gap in documented follow-up virologic monitoring during the early on-treatment period for patients receiving hepatitis C antiviral therapy.
-
Service type: Laboratory monitoring of hepatitis C viral load (quantitative HCV RNA) related to antiviral treatment follow-up
-
Typical site of service: Outpatient laboratory or clinic setting where hepatitis C treatment and monitoring occur (e.g., infectious disease clinic, hepatology clinic, outpatient infusion center, or outpatient laboratory)
Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with chronic hepatitis C infection begins direct-acting antiviral therapy (e.g., sofosbuvir/velpatasvir) in an outpatient infectious disease or hepatology clinic. Baseline evaluation includes HCV quantitative RNA (viral load) testing prior to treatment initiation. Clinical workflow calls for repeat HCV RNA quantitative testing between 4 and 12 weeks after treatment start to assess early virologic response and guide ongoing management. In this scenario, documentation in the chart lacks a recorded HCV quantitative RNA result in the 4–12 week window after antiviral initiation, and no reason is documented for the missing test. Typical sites of service include outpatient clinic, hospital outpatient infusion center, and community phlebotomy laboratory where blood is drawn for viral load measurement. The typical patient presentation includes recent diagnosis or treatment initiation for hepatitis C, prescription of antiviral therapy, and scheduled laboratory follow-up that was not captured in the medical record within the specified timeframe.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed the same day as specimen collection and meets E/M documentation criteria |